Tilray Brands, Inc.

TLRY Healthcare Drug Manufacturers Specialty & Generic

Tilray Brands, Inc.’s revenue for fiscal 2026 (year ended May 2026) was $915.5 million, up 11.5% from fiscal 2025. In the quarter to August 2026, revenue grew 22.7%, EPS was flat, free cash flow fell 36.6% and total debt rose 43.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

3.04 0.17 −5.30%
Market cap
$474.4M
P/E
0.0×
Fwd P/E
−14.8×
Dividend yield
—
F-score
3/9
Altman Z
−1.96
Beneish M
−2.01
Dividend safety
n/a
Aug '26 May '26 Feb '26 Nov '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
0.63 0.67 1.00 1.03
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
(36.84) (16.45) (39.03) (100.82)
P/B ratio
0.38 0.39 0.56 0.56
EV/Sales
0.77 0.83 1.04 1.04
EV/EBITDA
0.00 60.51 0.00 0.00
EV/FCF
(4.24) (4.81) (6.95) (8.58)
Current Ratio
1.88 2.21 2.79 2.81
Net Debt/EBITDA
(32.90) 13.11 (2.66) (2.79)
Debt/Equity
0.22 0.24 0.20 0.20
Earnings Yield
(30.20%) (19.67%) (179.61%) (283.46%)
Free Cash Flow Yield
(28.63%) (25.61%) (14.99%) (11.81%)
Free Cash Flow per Share
(0.21) (0.61) (0.21) (0.16)
Book value per Share
12.05 14.26 13.54 14.02
Free Cash Flow
(27.45) (68.60) (24.19) (18.10)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 13 Oct 2026